6MF2

Improved Model of Human Coagulation Factor VIII

6MF2 の概要

• エントリーDOI: 10.2210/pdb6mf2/pdb
• 関連するPDBエントリー: 2R7E 6MF0
• 分子名称: Coagulation factor VIII, beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, CALCIUM ION, ... (6 entities in total)
• 機能のキーワード: factor viii, hemophilia a, hemostasis, secreted, blood clotting
• 由来する生物種: Homo sapiens (Human); 詳細
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 175837.85

構造登録者

Smith, I.W.,Spiegel, P.C. (登録日: 2018-09-08, 公開日: 2019-09-11, 最終更新日: 2024-11-06)

主引用文献

Smith, I.W.,d'Aquino, A.E.,Coyle, C.W.,Fedanov, A.,Parker, E.T.,Denning, G.,Spencer, H.T.,Lollar, P.,Doering, C.B.,Spiegel Jr., P.C.
The 3.2 angstrom structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain.
J.Thromb.Haemost., 18:57-69, 2020

PubMed Abstract: Coagulation factor VIII represents one of the oldest protein-based therapeutics, serving as an effective hemophilia A treatment for half a century. Optimal treatment consists of repeated intravenous infusions of blood coagulation factor VIII (FVIII) per week for life. Despite overall treatment success, significant limitations remain, including treatment invasiveness, duration, immunogenicity, and cost. These issues have inspired research into the development of bioengineered FVIII products and gene therapies.

PubMed: 31454152
DOI: 10.1111/jth.14621

実験手法

X-RAY DIFFRACTION (3.6093641312 Å)